首页|Decoding m6A mRNA methylation by reader proteins in liver diseases

Decoding m6A mRNA methylation by reader proteins in liver diseases

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
N6-methyladenosine(m6A)is a dynamic and reversible epigenetic regulation.As the most prevalent internal post-transcriptional modification in eukaryotic RNA,it participates in the regulation of gene expression through various mechanisms,such as mRNA splicing,nu-clear export,localization,translation efficiency,mRNA stability,and structural transforma-tion.The involvement of m6A in the regulation of gene expression depends on the specific recognition of m6A-modified RNA by reader proteins.In the pathogenesis and treatment of liver disease,studies have found that the expression levels of key genes that promote or inhibit the development of liver disease are regulated by m6A modification,in which abnormal expres-sion of reader proteins determines the fate of these gene transcripts.In this review,we intro-duce m6A readers,summarize the recognition and regulatory mechanisms of m6A readers on mRNA,and focus on the biological functions and mechanisms of m6A readers in liver cancer,viral hepatitis,non-alcoholic fatty liver disease(NAFLD),hepatic fibrosis(HF),acute liver injury(ALI),and other liver diseases.This information is expected to be of high value to re-searchers deciphering the links between m6A readers and human liver diseases.

IGF2BPsLiver diseasesm6A modificationm6A readermRNA metabolismYTH domain protein

Lijiao Sun、Xin Chen、Sai Zhu、Jianan Wang、Shaoxi Diao、Jinyu Liu、Jinjin Xu、Xiaofeng Li、Yinogygin Sun、Cheng Huang、Xiaoming Meng、Xiongwen Lv、Jun Li

展开 >

Inflammation and Immune Mediated Diseases Laboratory of Anhui Province,Anhui Institute of Innovative Drugs,School of Pharmacy,Anhui Medical University,Hefei,Anhui 230032,China

The Key Laboratory of Anti-inflammatory and Immune Medicines,Anhui Medical University,Ministry of Education,Hefei,Anhui 230032,China

Institute for Liver Diseases of Anhui Medical University,ILD-AMU,Anhui Medical University,Hefei,Anhui 230032,China

Department of Nephropathy,The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230022,China

Department of Oncology,The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui 230032,China

展开 >

国家自然科学基金国家自然科学基金国家自然科学基金University Synergy Innovation Program of Anhui Province,China国家转基因重大专项

817706098197053482100627GXXT-2019-0452108085QH311

2024

10.1016/j.gendis.2023.02.054

基因与疾病(英文)

基因与疾病(英文)

ISSN：
年,卷(期)：2024.11(2)
  • 164